Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.

2024
Clinical Ophthalmology

View publication

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan; Singapore Eye Research Institute, Singapore National Eye Centre, Singapore; Duke-NUS Medical School, Singapore; Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Ophthalmology, Tri-Service General Hospital, Taipei, Taiwan; Sankara Nethralaya, Chennai, India; VST Centre for Glaucoma Care, Kallam Anji Reddy Campus, Hyderabad, India; Santen Pharmaceuticals, Inc, Emeryville, CA, United States; Santen Pharmaceuticals, Ltd, Osaka, Japan; Department of Ophthalmology, Seoul National University, Seoul, South Korea

Related Publications

Benefit of omidenepag isopropyl ophthalmic solution in treatment persistence in Japanese patients with glaucoma

Kashiwagi K., Nakano T., Nakazawa T., Fuwa M., Otsuka N., Shii D., Miyahara R.

Posterior Ciliary Artery Contraction by Bradykinin Receptor Subtypes and Implications for Retinal Blood Flow Dysfunction

Sharif NA, Ohia SE, Kulkarni-Chitnis M, Okolie A, Chaudhry SD, Njie-Mbye YF

Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A 3-Year Prospective Study

Akagi T, Fukuchi T, Higashide T, Udagawa S, Ohkubo S, Sugiyama K, Tanihara H, Araie M, Tomita G, Matsumoto C, Tomidokoro A, Hangai M, Kawata H, Inai M, Tanaka Y; SVF Prospector Study Group.

View all Glaucoma publications